Determinants of vegetable food choice in families with limited food budgets in England: a focus group study to inform vegetable promotion programmes - Volume 14

Australian researchers hope test is a ‘game-changer’ for accuratelydiagnosing those following a strict gluten-free diet

Small experiment monitored transfer of gluten after couples had kissed with tongues for at least one minute

Background Various oral manifestations are associated with coeliac disease in children, whereas data on adults are scarce. Moreover, possible individual factors predisposing to these manifestations re...

The results of an observational study from Lund University in Sweden are clear: up to the age of two, a more fibre-rich diet seems to reduce the risk

Celiac disease affects an estimated 1 percent of adults and children worldwide. Yet, many individuals endure years of symptoms before receiving a diagnosis. Studies suggest it can take more than a dec...

Children born in spring or summer with a specific gene variant may have a higher risk of celiac disease and lower levels of a key protein, according to a study, potentially helping future research on ...

There are currently no treatments available for celiac disease beyond a gluten-free diet. Several late-phase companies aim to change the paradigm and deliver hope and progress soon.

Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.

Patients with celiac disease face an increased risk of developing any chronic liver disease. This risk increase can persist for at least 25 years after celiac diagnosis. The findings, published in The...

Get involved with research into coeliac disease and the affects of gluten by helping with research projects.

Experts have used magnetic resonance imaging (MRI) to better understand the impact a gluten free diet has on people with coeliac disease, which could be the first step towards finding new ways of trea...

Up to 20% of patients with celiac disease may not respond to a gluten-free diet and would likely be classified as having non-responsive celiac disease.

Immunic Inc (NASDAQ:IMUX) announced that data from its Phase 1/1b clinical trial for IMU-856, a small molecule targeting SIRT6, has been published in The...